menu
    • menu
    [{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Genson Capital"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurenati Therapeutics

    Menu

    Neurenati Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Neurenati Therapeutics

    Canada arrow
    MAGHREB PHARMA
    Not Confirmed

    Neurenati Therapeutics

    Canada arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NEU-001

    Therapeutic Area : Gastroenterology

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Grants Orphan & Rare Pediatric Status to Neurenati’s NEU-001 for Hirschsprung

    Details : NEU-001 is a first-in-class, once-in-a-lifetime treatment administered intrarectally, which is being evaluated to treat Hirschsprung's disease.

    Product Name : NEU-001

    Product Type : Protein

    Upfront Cash : Inapplicable

    March 04, 2025

    Lead Product(s) : NEU-001

    Therapeutic Area : Gastroenterology

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Neurenati Therapeutics

    Canada arrow
    MAGHREB PHARMA
    Not Confirmed

    Neurenati Therapeutics

    Canada arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NEU-001

    Therapeutic Area : Gastroenterology

    Study Phase : Preclinical

    Sponsor : Investissement Québec

    Deal Size : $2.9 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Neurenati Concludes $1.7 Million Seed Financing with Support from Impulsion PME

    Details : The proceeds will be used to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease.

    Product Name : NEU-001

    Product Type : Protein

    Upfront Cash : Undisclosed

    April 18, 2024

    Lead Product(s) : NEU-001

    Therapeutic Area : Gastroenterology

    Highest Development Status : Preclinical

    Sponsor : Investissement Québec

    Deal Size : $2.9 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Neurenati Therapeutics

    Canada arrow
    MAGHREB PHARMA
    Not Confirmed

    Neurenati Therapeutics

    Canada arrow
    MAGHREB PHARMA
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NEU-001

    Therapeutic Area : Gastroenterology

    Study Phase : Preclinical

    Sponsor : Genson Capital

    Deal Size : $1.2 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Neurenati Completes $1.2 Million Seed Financing for NEU-001 in Hirschsprung Disease

    Details : The funding will accelerate the development of Neurenati's NEU-001, which is being evaluated in the preclinical studies for the treatment of Hirschsprung’s disease.

    Product Name : NEU-001

    Product Type : Protein

    Upfront Cash : Undisclosed

    February 29, 2024

    Lead Product(s) : NEU-001

    Therapeutic Area : Gastroenterology

    Highest Development Status : Preclinical

    Sponsor : Genson Capital

    Deal Size : $1.2 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth